Actively Recruiting
Evaluating EXV-802 and EXV-801 Capsules for Treating Agitation in Alzheimers Disease Dementia A Double-Blind, Placebo-Controlled Phase 23 Study
Led by Exciva GmbH · Updated on 2026-08-14
300
Participants Needed
49
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two drugs, EXV-802 and EXV-801, for treating agitation in people with Alzheimers Disease dementia. This Phase 23 study uses a double-blind, placebo-controlled design and includes approximately 300 participants diagnosed with Alzheimers-related agitation using standardized criteria and biomarker confirmation. The study is conducted at multiple centers across the US, Canada, and Europe. Participants are randomly assigned to one of three groups receiving EXV-802 capsules, EXV-801 capsules, or placebo capsules, each taken twice daily for six weeks. Screening occurs about four weeks before randomization to ensure eligibility, and the study follows a parallel model comparing these three arms. Treatment adherence and response are carefully monitored during this period. During the study, participants undergo assessments including the Cohen-Mansfield Agitation Inventory CMAI-IPA to measure agitation changes from baseline to week 6, and the Clinical Global Impression of Severity CGI-S scale to evaluate symptom severity. Caregivers must be involved and regularly in contact with participants. Safety and efficacy data are collected throughout, with the study expected to complete by early 2029.
CONDITIONS
Brief Title
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Research Team
E
Exciva Clinical Studies
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here